T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker.
FGFR1
PCM1-JAK2
PDGFRA
PDGFRB
T-cell
eosinophilia
lymphoblastic
lymphoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Jun 2021
21 Jun 2021
Historique:
received:
31
03
2021
revised:
14
06
2021
accepted:
18
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia (M/LNs-Eo), a group of diseases with gene fusion resulting in overexpression of an aberrant tyrosine kinase or cytokine receptor. The correct identification of this category has relevant therapeutic implications. LIM domain only 2 (LMO2) is overexpressed in most T-LBL, but not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations (iT-LBP). We retrospectively evaluated 11 cases of T-LBL occurring in the context of M/LNs-Eo. Clinical, histological, immunohistochemical and molecular features were collected and LMO2 immunohistochemical staining was performed. The critical re-evaluation of these cases confirmed the diagnosis of T-LBL with morphological, immunohistochemical and molecular features consistent with T-LBL occurring in M/LNs-Eo. Interestingly, LMO2 immunohistochemical analysis was negative in 9/11 cases, whereas only 2 cases revealed a partial LMO2 expression with a moderate and low degree of intensity, respectively. LMO2 may represent a potentially useful marker to identify T-LBL developing in the context of M/LNs-Eo. In this setting, T-LBL shows LMO2 immunohistochemical profile overlapping with cortical thymocytes and iT-LBP, possibly reflecting different molecular patterns involved in the pathogenesis of T-LBL arising in the setting of M/LNs-Eo.
Sections du résumé
BACKGROUND
BACKGROUND
Rarely, T-lymphoblastic lymphoma (T-LBL) may develop in the setting of myeloid/lymphoid neoplasms with eosinophilia (M/LNs-Eo), a group of diseases with gene fusion resulting in overexpression of an aberrant tyrosine kinase or cytokine receptor. The correct identification of this category has relevant therapeutic implications. LIM domain only 2 (LMO2) is overexpressed in most T-LBL, but not in immature TdT-positive T-cells in the thymus and in indolent T-lymphoblastic proliferations (iT-LBP).
METHODS AND RESULTS
RESULTS
We retrospectively evaluated 11 cases of T-LBL occurring in the context of M/LNs-Eo. Clinical, histological, immunohistochemical and molecular features were collected and LMO2 immunohistochemical staining was performed. The critical re-evaluation of these cases confirmed the diagnosis of T-LBL with morphological, immunohistochemical and molecular features consistent with T-LBL occurring in M/LNs-Eo. Interestingly, LMO2 immunohistochemical analysis was negative in 9/11 cases, whereas only 2 cases revealed a partial LMO2 expression with a moderate and low degree of intensity, respectively.
CONCLUSIONS
CONCLUSIONS
LMO2 may represent a potentially useful marker to identify T-LBL developing in the context of M/LNs-Eo. In this setting, T-LBL shows LMO2 immunohistochemical profile overlapping with cortical thymocytes and iT-LBP, possibly reflecting different molecular patterns involved in the pathogenesis of T-LBL arising in the setting of M/LNs-Eo.
Identifiants
pubmed: 34205834
pii: cancers13123102
doi: 10.3390/cancers13123102
pmc: PMC8234657
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Leukemia. 2007 Jun;21(6):1183-8
pubmed: 17377585
Acta Haematol. 2002;107(2):101-7
pubmed: 11919391
Am J Hematol. 2019 Oct;94(10):1149-1167
pubmed: 31423623
Ann Hematol. 2015 Nov;94(11):1927-8
pubmed: 26202607
BMC Pulm Med. 2019 Nov 19;19(1):216
pubmed: 31744552
Leuk Res. 2020 Dec;99:106460
pubmed: 33166908
Eur J Haematol. 2012 Jul;89(1):37-41
pubmed: 22587685
Br J Haematol. 2014 Sep;166(6):809-17
pubmed: 24913195
Science. 2010 Feb 12;327(5967):879-83
pubmed: 20093438
Histopathology. 2020 Dec;77(6):984-988
pubmed: 32526041
Leukemia. 2008 Jul;22(7):1434-7
pubmed: 18079736
Histopathology. 2012 Jul;61(1):33-46
pubmed: 22394247
Am J Clin Pathol. 2015 Sep;144(3):411-22
pubmed: 26276771
J Clin Oncol. 2008 Jan 20;26(3):447-54
pubmed: 18086797
Leuk Lymphoma. 2018 Jul;59(7):1672-1676
pubmed: 29119847
Am J Clin Pathol. 2021 Feb 4;155(2):160-178
pubmed: 33367495
EMBO J. 1996 Mar 1;15(5):1021-7
pubmed: 8605871
Ann Oncol. 2018 Aug 1;29(8):1880-1882
pubmed: 29767670
N Engl J Med. 2004 Apr 29;350(18):1828-37
pubmed: 15115829
Am J Clin Pathol. 2015 Sep;144(3):377-92
pubmed: 26276769
J Natl Compr Canc Netw. 2020 Sep;18(9):1248-1269
pubmed: 32886902
Blood. 2007 Feb 15;109(4):1636-42
pubmed: 17038524
Am J Surg Pathol. 2008 Jan;32(1):14-20
pubmed: 18162765
Blood. 2006 Nov 15;108(10):3520-9
pubmed: 16873670
Mod Pathol. 2019 Apr;32(4):490-498
pubmed: 30401948
Am J Clin Pathol. 2020 Aug 5;154(3):305-318
pubmed: 32525541
N Engl J Med. 2004 Feb 26;350(9):913-22
pubmed: 14985489
Cancers (Basel). 2020 Apr 05;12(4):
pubmed: 32260556
Blood. 2017 Feb 9;129(6):704-714
pubmed: 28028030
Hematol Oncol Clin North Am. 2017 Aug;31(4):643-661
pubmed: 28673393
Am J Clin Pathol. 2016 Feb;145(2):180-90
pubmed: 26796495
Hum Pathol. 2010 Apr;41(4):461-76
pubmed: 20226962
Eur J Haematol. 2016 May;96(5):447-60
pubmed: 26679753
Nat Rev Cancer. 2013 Feb;13(2):111-22
pubmed: 23303138